|
1.
|
|
9 p, 821.4 KB |
Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma : Final Results of a Randomized Phase III Study
/
Kwak, Larry W. (Comprehensive Cancer Center, Duarte) ;
Sancho, Juan Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Cho, Seok Goo (The Catholic University of Korea, Seoul, South Korea) ;
Nakazawa, Hideyuki (Shinshu University School of Medicine, Nagano, Japan) ;
Suzumiya, Junji (Shimane University Hospital, Innovative Cancer Center/Oncology-Hematology, Izumo, Japan) ;
Tumyan, Gayane (Division of Hematology and Bone Marrow Transplantation, Blokhin Russian Cancer) ;
Kim, Jin Seok (Yonsei University College of Medicine, Severance Hospital, Seoul, South Korea) ;
Menne, Tobias (Newcastle University, UK) ;
Mariz, José (Instituto Português de Oncología do Porto) ;
Ilyin, Nikolai (Ministry of Health of the Russian Federation) ;
Jurczak, Wojciech (Maria Sklodowska-Curie National Research Institute of Oncology, Kraków, Poland) ;
Lopez Martinez, Aurelio (Hospital Arnau de Vilanova (València)) ;
Samoilova, Olga (Nizhniy Novgorod Region Clinical Hospital, Nizhniy Novgorod, Russia) ;
Zhavrid, Edvard (N. N. Alexandrov Republican Scientific and Practical Centre of Oncology and Medical Radiology, Belarus) ;
Yañez Ruiz, Eduardo (Universidad de la Frontera, Temuco, Chile) ;
Trneny, Marek (Charles University, Czech Republic) ;
Popplewell, Leslie (Toni Stephenson Lymphoma Cancer Center and Department of Hematology and Hematopoietic Cell Transplantation, Duarte, CA) ;
Ogura, Michinori (Kasugai Municipal Hospital, Aichi 486-8510, Japan.) ;
Kim, Wong Seog (Sungkyunkwan University School of Medicine, Seoul, South Korea) ;
Lee, Sang Joon (Celltrion. Inc, South Korea) ;
Kim, Sung Hyun (Celltrion. Inc, South Korea) ;
Ahn, Keum Young (Celltrion. Inc, South Korea) ;
Buske, Christian (University Hospital of Ulm, Germany)
Introduction: This double-blind, parallel-group, active-controlled phase III trial (NCT02260804) assessed CT-P10 and rituximab safety and efficacy in patients with previously untreated low-tumor-burden follicular lymphoma (LTBFL), including after a single switch from rituximab to CT-P10. [...]
2022 -  10.1016/j.clml.2021.08.005
Clinical Lymphoma, Myeloma & Leukemia, Vol. 22 Núm. 2 (february 2022) , p. 89-97
|
|
|
2.
|
|
9 p, 1.9 MB |
Management and outcomes of patients with left atrial appendage thrombus prior to percutaneous closure
/
Marroquin, Luis (Hospital Clinico San Carlos. IdISSC. Cardiología Intervencionista. Instituto Cardiovascular) ;
Tirado-Conte, Gabriela (Interventional Cardiology. Cardiovascular Institute. Hospital Clinico San Carlos. IdISSC) ;
Pracoń, Radosław (Department of Coronary and Structural Heart Diseases. National Institute of Cardiology) ;
Streb, Witold (Silesian Centre for Heart Disease) ;
Gutierrez, Hipolito (Cardiology. Clinic University Hospital) ;
Boccuzzi, Giacomo (Cardiology. Ospedale San Giovanni Bosco) ;
Arzamendi, Dabit (Institut d'Investigació Biomèdica Sant Pau) ;
Cruz-González, Ignacio (Cardiology. Hospital Universitario de Salamanca. IBSAL. CIBER CV) ;
Ruiz Nodar, Juan Miguel (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Kim, Jung-Sun (Severance Cardiovascular Hospital) ;
Freixa, Xavier (Cardiology. Hospital Clinic of Barcelona) ;
Lopez Minguez, Jose Ramon (Cardiology. Hospital Universitario de Badajoz) ;
De Backer, Ole (Cardiology. Rigshospitalet) ;
Ruiz-Salmeron, Rafael (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Dominguez, Antonio (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
McInerney, Angela (Interventional Cardiology. Cardiovascular Institute. Hospital Clinico San Carlos. IdISSC) ;
Peral, Vicente (Cardiology. Hospital Universitario Son Espases. Health Research Institute of the Balearic Islands (IdISBa)) ;
Estevez-Loureiro, Rodrigo (Cardiology. University Hospital Complex Vigo) ;
Fernandez-Nofrerias, Eduard (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Freitas-Ferraz, Afonso B. (Cardiology. Quebec Heart and Lung Institute. Laval University) ;
Saia, Francesco (Cardiology. University Hospital of Bologna) ;
Huczek, Zenon (1st Department of Cardiology. Medical University of Warsaw) ;
Gheorghe, Livia (Hospital Universitario Puerta del Mar (Cadis, Andalusia)) ;
Salinas, Pablo (Interventional Cardiology. Cardiovascular Institute. Hospital Clinico San Carlos. IdISSC) ;
Demkow, M. (Department of Coronary and Structural Heart Diseases. National Institute of Cardiology) ;
Delgado-Arana, J.R. (Cardiology. Clinic University Hospital) ;
Fernandez Peregrina, E.E. (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Kalarus, Z. (Silesian Centre for Heart Disease) ;
Elvira Laffond, A. (Cardiology. Hospital Universitario de Salamanca. IBSAL. CIBER CV) ;
Jang, Y. (Severance Cardiovascular Hospital) ;
Fernandez Camacho, J.C. (Cardiology. Hospital Universitario de Badajoz) ;
Lee, O.H. (Severance Cardiovascular Hospital) ;
Hernández-Garcia, J.M. (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ;
Mas-Llado, C. (Cardiology. Hospital Universitario Son Espases. Health Research Institute of the Balearic Islands (IdISBa)) ;
Caneiro-Queija, Berenice (Cardiology. University Hospital Complex Vigo) ;
Amat-Santos, Ignacio J (Cardiology. Clinic University Hospital) ;
Dabrowski, M. (Interventional Cardiology and Angiology Clinic. National Institute of Cardiology) ;
Rodes-Cabau, Josep (Cardiology. Quebec Heart and Lung Institute. Laval University) ;
Nombela-Franco, Luís (Interventional Cardiology. Cardiovascular Institute. Hospital Clinico San Carlos. IdISSC)
Objective: Left atrial appendage (LAA) thrombus has heretofore been considered a contraindication to percutaneous LAA closure (LAAC). Data regarding its management are very limited. The aim of this study was to analyse the medical and invasive treatment of patients referred for LAAC in the presence of LAA thrombus. [...]
2023 - 10.1136/heartjnl-2021-319811
Heart, 2023
|
|
|
3.
|
|
10 p, 667.7 KB |
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma : a cytogenetic subgroup analysis of POLLUX
/
Kaufman, J. L. (Winship Cancer Institute. Emory University) ;
Dimopoulos, Meletios (The National and Kapodistrian University of Athens) ;
White, D. (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ;
Benboubker, L. (Service d'Hématologie et Thérapie Cellulaire. Hôpital Bretonneau. Centre Hospitalier Régional Universitaire) ;
Cook, G. (St James's Institute of Oncology. Leeds Teaching Hospitals National Health Service Trust and University of Leeds) ;
Leiba, M. (Assuta Ashdod University Hospital. Faculty of Health Science Ben-Gurion University of the Negev) ;
Morton, J. (Icon Cancer Care) ;
Joy Ho, P. (Institute of Haematology. Royal Prince Alfred Hospital) ;
Kim, K. (Department of Medicine. Samsung Medical Center. Sungkyunkwan University School of Medicine) ;
Takezako, N. (Department of Hematology. National Hospital Organization Disaster Medical Center of Japan) ;
Moreau, Philippe (Hematology. University Hospital Hôtel-Dieu) ;
Sutherland, H. J. (Leukemia/Bone Marrow Transplant Program. University of British Columbia) ;
Magen, H. (Department of Hematology Chaim Sheba Medical Center. Ramat-Gan. Sackler Faculty of Medicine. Tel Aviv University) ;
Iida, S. (Department of Hematology and Oncology. Nagoya City University Graduate School of Medical Sciences) ;
Kim, J. S. (Yonsei University College of Medicine. Severance Hospital) ;
Miles Prince, H. (Cabrini Hospital. Epworth HealthCare and Sir Peter MacCallum Department of Oncology. University of Melbourne) ;
Cochrane, T. (Gold Coast University Hospital and Griffiths University) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bahlis, N. J. (University of Calgary. Arnie Charbonneau Cancer Institute) ;
Chari, Ajai (Icahn School of Medicine at Mount Sinai) ;
O'Rourke, L. (Janssen Research & Development) ;
Trivedi, S. (Janssen Research & Development) ;
Casneuf, T. (Janssen Research & Development) ;
Krevvata, M. (Janssen Research & Development) ;
Ukropec, J. (Janssen Global Medical Affairs) ;
Kobos, R. (Janssen Research & Development) ;
Avet-Loiseau, Hervé (Unite de Genomique du Myelome. IUC-Oncopole) ;
Usmani, S. Z. (Levine Cancer Institute/Atrium Health) ;
San-Miguel, J. (Clínica Universidad de Navarra. Centro de Investigación Médica Aplicada) ;
Universitat Autònoma de Barcelona
High cytogenetic risk abnormalities confer poor outcomes in multiple myeloma patients. In POLLUX, daratumumab/lenalidomide/dexamethasone (D-Rd) demonstrated significant clinical benefit versus lenalidomide/dexamethasone (Rd) in relapsed/refractory multiple myeloma (RRMM) patients. [...]
2020 - 10.1038/s41408-020-00375-2
Blood Cancer Journal, Vol. 10 Núm. 11 (january 2020) , p. 111
|
|
|
4.
|
|
10 p, 990.6 KB |
Brain hemorrhage recurrence, small vessel disease type, and cerebral microbleeds
/
Charidimou, Andreas ;
Imaizumi, Toshio ;
Moulin, Solene ;
Biffi, Alessandro ;
Samarasekera, Neshika ;
Yakushiji, Yusuke ;
Peeters, Andre ;
Vandermeeren, Yves ;
Laloux, Patrice ;
Baron, Jean-Claude ;
Hernandez-Guillamon, Mar ;
Montaner, Joan (Hospital Universitari Vall d'Hebron) ;
Casolla, Barbara ;
Gregoire, Simone M. ;
Kang, Dong-Wha ;
Kim, Jong S. ;
Naka, H. ;
Smith, Eric E. ;
Viswanathan, Anand ;
Jäger, Hans Rolf ;
Al-Shahi Salman, Rustam ;
Greenberg, Steven M. ;
Cordonnier, Charlotte ;
Werring, David J. ;
Universitat Autònoma de Barcelona
We evaluated recurrent intracerebral hemorrhage (ICH) risk in ICH survivors, stratified by the presence, distribution, and number of cerebral microbleeds (CMBs) on MRI (i. e. , the presumed causal underlying small vessel disease and its severity). [...]
2017 - 10.1212/WNL.0000000000004259
Neurology, Vol. 89 (august 2017) , p. 820-829
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
